Screening History, Stage at Diagnosis, and Mortality in Screen-Detected Breast Cancer
In this cohort study of older women with screen-detected estrogen receptor-positive or human epidermal growth factor receptor 2-negative breast cancer, prior screening mammography was associated with earlier stage at breast cancer diagnosis and lower breast cancer mortality. These findings support the potential for routine screening to improve breast cancer outcomes. As with all observational studies, this study is limited by the potential effects of other differences between the screening and nonscreening groups.
Authors
- Haiying Zhan (ORCID: https://orcid.org/0009-0009-2233-9551)
- Jane Fan
- Timothy J. Robinson (ORCID: https://orcid.org/0000-0002-7220-8850)
- Eric P. Winer (ORCID: https://orcid.org/0000-0002-8819-1723)
- Maryam B. Lustberg (ORCID: https://orcid.org/0000-0001-8559-5645)
- Michaela A. Dinan (ORCID: https://orcid.org/0000-0003-4849-4743)
- Sarah J. Westvold (ORCID: https://orcid.org/0009-0004-2060-2137)
- Pamela R. Soulos
- Sida Huang
- John Lewin
Institutions
- Yale Cancer Center (US)
- Yale University (US)
- Yale New Haven Health System (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-04-15
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.5322
- Citations
- 8
- Primary Topic
- Global Cancer Incidence and Screening
- Type
- article
- Field-Weighted Citation Impact
- 8.36
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- California Department of Public Health
- Yale University
- Gilead Sciences
- University of Southern California
- Yale Cancer Center
- Centers for Disease Control and Prevention
- National Cancer Institute